Aims: RPR 102681, a cholecystokinin-B antagonist, increased dopamine (DA) release and reduced cocaine self-administration in animals. This pilot study sought to assess the safety and pharmacokinetics (PK) of co-administration of RPR 102681 and cocaine, and to confirm the DA release mechanism of RPR 102681.
| INTRODUC TI ON
Cocaine addiction is a major public health problem with marked morbidity and mortality. In 2016 in the United States, 14.40% of people aged 12 years or older in the National Survey on Drugs and Health (NSDUH) reported lifetime cocaine use. 1 A variety of strategies are being pursued to find an effective agonist or antagonist medication treatment for cocaine dependency 2,3 without abuse liability. A new approach that utilizes cholecystokinin-B (CCK-B) receptor antagonists was tested in animal models and early phase I safety human volunteer studies. CCK-B is co-localized with dopamine (DA) in certain mesolimbic dopaminergic neurons. [4] [5] [6] [7] CCK-B receptors are widely distributed in the brain, especially in DA-rich regions, and there is evidence for an antagonistic CCK-B/DA receptor interaction in the nucleus accumbens regulating DA transmission. 8 Repetitive cocaine administration activates the mesolimbic CCK system, 9 CCK-B receptor antagonists effectively reduced both cocaine consumption and cocaine withdrawal-associated anxiety in animal models of addiction. 10 A selective non-peptide antagonist of the CCK-B receptors with high affinity for human receptors 11, 12 is orally bioavailable and readily penetrates the blood-brain barrier and can be detected in rat brain as early as 15-30 minutes after oral administration. 13, 14 Intraperitoneal administration of RPR 102681 stimulated DA release in the ventral striatum (VS) of rats, nearly tripling the baseline levels when given at the highest dose tested (20 mg/kg). [15] [16] [17] RPR 102681 reduces amphetamine and cocaine selfadministration in drug-naïve mice and drug-experienced rats but does not alter cocaine-or amphetamine-induced place preference; [18] [19] [20] [21] it also reduces alcohol and "pleasurable" food consumption in rats and monkeys. 22 In addition, RPR 102681 was shown to be safe in animal studies 23 with no abuse liability. 17 In 2 clinical studies with RPR 102681 in healthy volunteers conducted in France, there were no serious adverse events (AEs). 23, 24 The current phase Ib pilot study of the safety, tolerability, and pharmacokinetics (PK) of RPR 102681 in cocaine-dependent subjects is required by the FDA before determining its efficacy as a pharmacological treatment for cocaine abuse in outpatient setting. The study also sought to assess the abuse liability of RPR 102681 in man and to evaluate whether treatment with RPR 102681 altered subjective effects of cocaine, cocaine craving, and mood. Furthermore, this study aimed to validate the dopaminergic agonist effects of RPR 102681 seen in animal studies [15] [16] [17] by measuring change from baseline of DA release in the striatum using [ 11 C]raclopride positron emission tomography (PET) imaging. The trial was registered at www. ClinicalTrials.gov with the identifier NCT00067535.
| ME THODS

| Participants
Participants met Diagnostic and statistical manual of mental disorders 4th edition (DSM-IV) criteria 25 for current cocaine abuse or cocaine dependence ascertained by at least 1 positive urine benzoylecgonine (BE) test. 26 The work was carried out in accordance with the recommendations of the World Medical Association in the WMA Declaration of Helsinki. 27 The study was approved by the Institutional Review Boards of the Johns Hopkins University School of Medicine in Baltimore, Maryland, and the Uniformed Services University of the Health Sciences in Bethesda, Maryland. All participants provided written informed consent to take part in this study after being fully informed about potential risks of participation.
| Study design
The outline for this inpatient, dose-escalation, placebo-controlled, double-blind study is shown in Figure 1 
| Drugs
| Behavioral and subjective measures
Cocaine subjective effects were measured using the Visual Analog Scale (VAS) administered 15 minutes before, and at 5, 15, 25 and 35 minutes after each IV infusion where subjects reported the degree to which they felt on a continuous scale digitized between 0 and 100 for computing a score. 28 Craving was measured by the Brief Substance Craving Scale (BSCS) 29 on days 2-28 every other day and on Day 35, which is a self-administered assessment that asks the subject to rate his or her craving for the primary drug cocaine, and craving for any secondary drugs or alcohol.
Mood symptoms were assessed by the Profile of Mood States (POMS) 30 at screening and every other day, until the end of the study.
Abuse liability was measured by the Addiction Research Center
Inventory (ARCI). 31 The ARCI consists of 49 statements in a true/ false format and contains 5 subscales: A (Amphetamine), BG (energy), MBG (euphoria), LSD (dysphoria), and PCAG (sedation).
| Physiological measures
Before and after each IV infusion, each participant's physiologic responses were closely monitored using repeated heart rate (HR), blood pressure (BP), and electrocardiogram (ECG) readings.
| Positron emission tomography
Following randomization, participants underwent a baseline PET scan. PET was performed at Johns Hopkins Hospital in Baltimore, Maryland, on a GE Advance scanner for 90 minutes after the intravenous injection of 740 MBq (20 mCi) [ 11 C]raclopride for baseline 3 days before the first dose of RPR 102681 and 5 days after each dose increment of RPR 102681 at steady-state for that dose level.
The dosing schedule for PRP 102681 was changed for the final 4 participants to allow the performance of PET scans at C max of RPR 102681 (90 minutes after second daily dose) instead of steady state.
During the PET scans, blood samples were drawn to measure plasma levels of RPR 102681.
Magnetic resonance imaging (MRI) scans for anatomic localization were performed on a 1.5 T GE Signa system to localize the anterior commissure-posterior commissure (AC-PC) line to allow standardized positioning across the subjects based on the anatomical landmarks relevant to this study. 32 The entire 90 minutes of PET images were then processed. The regions of interest (ROIs), including the caudate nucleus, the putamen, the VS, and the cerebellum (reference tissue), were manually drawn on the co-registered MRI images. 33 The cerebellar time-activity curve was obtained by applying ROIs of cerebellum to the dynamic PET images. To measure the specific binding of tracer, the nondisplaceable binding potential F I G U R E 1 Design of the inpatient, dose-escalation, placebo-controlled, double-blind study of RPR 102681 in patients with cocaine abuse/dependence ((BP ND ) 34 images were generated by a simplified reference model with a linear regression algorithm, 35 where the cerebellar timeactivity curve was used as reference tissue input function. The ROIs BP ND ) values were obtained by applying ROIs to the BP ND images. Intrasynaptic DA release in the striatum was estimated by the difference in the nondisplaceable binding potential (BP ND (df)) as follows:
where BP ND (baseline) is the nondisplaceable mean of the [ 11 C]raclopride binding potentials (BP ND s) 33 
| Pharmacokinetic assays
Blood samples were collected for assessment of cocaine BE PK on 
| Data analysis
The primary outcome measures were AEs and cardiovascular responses (HR, BP, ECG). Data concerning AEs was compiled for RPR 102681 and placebo cohorts and presented as summary statistics. No corrections for multiple comparisons were included in the analysis since this was an early exploratory pilot study.
| RE SULTS
| Demographics and drug use
Twenty participants were enrolled, 19 (Table 1) 
| Adverse events
During the study period, 18 of 19 subjects experienced a total of 119 mild or moderate AEs. Of the subjects who experienced AEs, 15 experienced a total of 72 AEs that were considered at least possibly related to study medication. The most frequent AEs for both RPR 102681 and placebo groups were headache (26%), nausea (21%), flatulence (21%), and irritability (21%). Headaches and flatulence were reported in previous studies with RPR 102681. 23, 24 No events were statistically more likely to occur in the RPR 102681 group as compared to the placebo group. One subject experienced treatment-emergent flatulence and subsequently requested withdrawal. No serious AEs or deaths were reported during the study.
| Cardiovascular safety
There was no clinically meaningful difference among study groups for the mean change in oral temperature, respiratory rate, systolic Thus, PR/R-R/QT duration in the RPR 102681 group seemed to decrease following cocaine 40 mg infusion; however, all changes were within normal ranges and were not clinically significant (Figure 3 ).
| Pharmacokinetics
Eleven subjects in the RPR 102681 group had RPR 102681 plasma concentration data available for at least 2 of the last 3 days of treatment at each dose level; and were included in the dose proportionality analysis ( 
| Positron emission tomography scans results
The BP ND at all 3 ROIs indicated that DA D 2 receptor availability was significantly higher than baseline in the caudate (t test, P < .001) and
the VS (t test, P < .0001) for the 4 participants who received the 2 daily doses of RPR 102681 with early dosing before PET scans at 9.15 and 1.5 hours before the beginning of the PET scans (Figures 4a,b Participants were people with cocaine abuse or cocaine dependence who had received the given dose of RPR 102681 or placebo for 5 d. Participants (N = 5) treated with placebo received the placebo twice daily for the duration of the study. Participants treated with RPR 102681 (N = 11) received half of the daily dose at 6 am and half at 6 pm throughout the study except on the day of the scans. Participants with the half daily dose before the PET scan (N = 7) had received the first dose, half the total daily dose 9.15 h before the start of the PET scans and the second dose after the PET scans. Participants with the full daily dose before the PET scan (N = 4) had received the first dose, half the total daily dose 9.15 h before the start of the PET scans and the second dose 1.5 h before the start of the PET scans. The BP ND of the participants with the full daily dose before the PET scans at each of the doses of RPR 102681 were significantly greater than the BP ND at baseline in the caudate (t test, P < .001) (upper panel) and the ventral striatum (t test, P < .0001) (lower panel)
The mean plasma concentrations of RPR 102681 at 1600 for the 4 participants who received 2 doses of RPR, the full daily dose, before PET scans ( 
| Behavioral and subjective effects
An examination of effects of cocaine administration responses on VAS 28 revealed that the higher RPR doses lowered subjects' response to cocaine except for the "depressed" and "anxious" components. At cocaine 20 mg, most significant effects occurred when the Total craved drug scores of the BSCS 29 for PRP and placebo were subjected to repeat measurement analysis for the days (days 2-28) measured. There was no significant RPR 102681 effect on first craved drug (cocaine) or second craved drug (nicotine, alcohol, and marijuana). However, the averaged craved drug 1 (cocaine) total score tends to be lower in the RPR group compared to placebo from on all days measured except for 1 day (day 26) (Table 4 ).
Repeated measure analysis of the POMS 30 showed a marginally higher significant value for the RPR 102681 group as compared with placebo for the "vigor" category (P = .044).
Overall, maximum values for the 5 ARCI 31 subscales following saline infusion were similar to those pre-infusion, while maximum ARCI values following cocaine infusion were higher than those following saline infusion or pre-infusion. In addition, a repeated measure analysis with adjustments for study day by cocaine level found no significant association between treatment groups and the changes in ARCI subscales due to cocaine infusion. Although these results do not indicate that RPR 102681 can decrease the abuse potential of cocaine, they demonstrate that RPR 102681 itself does not have any abuse potential.
| CON CLUS ION
RPR 102681 was well tolerated in this study; AEs were mild and consistent with those previously reported in other human studies. 23, 24 In addition, RPR 102681 had little additive cardiovascular effect when co-administered with cocaine.
Biotransformation of RPR 102681 is carried out in liver microsomes by cytochrome P450 3A4 (CYP3A4), and a small portion of cocaine is oxidized to the active metabolite norcocaine by CYP3A.
Since both RPR 102681 and cocaine are substrates for the same liver enzyme, there was the possibility of a RPR 102681-cocaine interaction that might lead to inhibition of their metabolism by CYP3A.
However, RPR 102681 did not alter the PK of either cocaine or its metabolite BE. RPR 102681 PK in this study found to be nonlinear, These differences in PK may result in part from variations in the activity of CYP3A4 37 or due to age differences.
The BP ND s at all 3 RPR 102681 dose levels were significantly higher than baseline in the caudate and the VS for the 4 participants who received the early dosing; there was no apparent dosedependent effect possibly due to the small sample size. It is possible that future studies with larger sample sizes will demonstrate a dosedependent effect.
The higher BP ND s at all 3 RPR 102681 dose levels probably reflect decrements in endogenous DA at the DA D 2 receptors after the administration of RPR 102681. The discrepancy between the radiotracer bindings observed with and without early dosing before PET scans can be explained by the possible mechanism that RPR 102681 likely binds to the DA D 2 receptor after a period of time. 38 Additionally, the metabolism of RPR 102681 may alter the cellular environment leading to transient externalization of DA D 2 receptors 39 resulting in temporarily increased BP ND s. An alternative hypothesis could be an increase in autoreceptor affinity of DA D 2 for [ 11 C]raclopride in the presence of RPR 102681. 8 Contrary to the increased intrasynaptic DA after the administration of RPR 102681 predicted by the animal study, 12 RPR 102681 briefly increased radiotracer binding in the caudate and the VS in humans with cocaine abuse and cocaine dependence, which makes it unlikely candidate as an agonist substitution medication for cocaine, but with a sample size of 4, these results may be spurious.
The role of CCK receptors types A and B in drug reward has been investigated in the various biological and behavioral processes related to drug abuse. 40, 41 CCK receptor subtypes have been found to have many differences in their mediation of behavioral and physiological function, [42] [43] [44] [45] where CCK-B receptor-mediated mechanisms inhibit, while CCK-A facilitated, the conditioned activity produced by cocaine in rats, and the relapse to cocaine use under stress. 46 Increased DA release in response to drug cues, was reported in human PET studies, which correlated with craving scores, and drugs that decrease DA transmission were proposed as possible "anti-craving" medications. 47, 48, 49 Overall, this study showed that RPR 102681 is safe and has no potential for abuse at the doses tested and no PK interactions with cocaine. The trend change in cocaine craving scores on RPR 102681 along with the PET findings need to be explored further in a properly powered study focusing on cue craving for possible clinical role of RPR 102681 in reducing craving to cocaine.
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